Why it matters
The result may be relevant to patients and cancer-care researchers, but the supplied reports do not establish whether or when the drug could be available in the United States.
RESEARCH & TREATMENTS • CHINA
Chinese phase III trial reports benefit from investigational breast cancer drug
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
This event has left the current brief. The summary below describes the stored record; open the original sources for current conditions.
BLUF
A Chinese phase III trial found that investigational trastuzumab rezetecan reduced the risk of disease progression or death in people with HER2-low metastatic breast cancer. The supplied reports give no effect size or information on approval or availability.
HOW THIS BRIEF WAS MADE 2 outlets: 2 specialist. Automated sourcing and summaries by the BLUF engine. Corrections